accord
unaid
approxim
million
peopl
worldwid
live
human
immunodefici
viru
hiv
http
wwwunaidsorg
introduct
highli
activ
antiretrovir
drug
ard
mainli
includ
nucleosidenonnucleosid
revers
transcriptas
inhibitor
nrtisnnrti
proteas
inhibitor
pi
integras
inhibitor
ini
howev
longterm
use
ard
caus
emerg
multidrug
resist
hiv
strain
result
treatment
failur
first
peptidebas
hiv
entri
inhibitor
enfuvirtid
approv
us
fda
clinic
use
treat
hivaid
patient
fail
respond
current
ard
ard
must
enter
host
cell
target
enzym
requir
hiv
replic
instead
hiv
entri
inhibitor
enter
host
cell
rather
act
outsid
cell
block
hiv
entri
target
cell
interact
envelop
glycoprotein
env
surfac
virion
far
seri
protein
peptidebas
hiv
entri
inhibitor
develop
preclin
clinic
studi
env
approxim
kd
also
known
compris
two
noncoval
bound
subunit
surfac
subunit
transmembran
subunit
upon
matur
play
key
role
viral
entri
entri
initi
bind
receptor
figur
induc
viral
recognit
proxim
cell
exposur
coreceptor
bind
site
corb
figur
conform
chang
complex
result
releas
subunit
trigger
fusion
viralcel
membran
specif
fusion
peptid
fp
insert
target
cell
membran
form
extend
prehairpin
intermedi
phi
conform
link
viru
cell
membran
figur
phi
undergo
conform
chang
three
ntermin
heptad
repeat
nhr
form
inner
core
three
ctermin
heptad
repeat
chr
encapsul
nhr
trimer
antiparallel
manner
form
sixhelix
bundl
figur
therebi
form
fusion
pore
caus
releas
genom
target
cell
entri
figur
varieti
substanc
work
cooper
synergist
viralcel
membran
fusion
creat
complex
interact
network
involv
varieti
proteinprotein
interact
nhrchr
interact
intracellular
extracellular
region
entri
inhibitor
target
protein
interfac
site
block
viral
invas
divid
three
major
subclass
adhes
inhibitor
target
block
interact
coreceptor
inhibitor
target
inhibit
bind
coreceptor
fusion
inhibitor
target
interfer
conform
chang
requir
viral
fusion
entri
addit
inhibitor
target
may
stronger
inhibitori
activ
higher
genet
barrier
also
forefront
current
research
review
discuss
characterist
protein
peptidebas
inhibitor
specif
target
hiv
env
look
ahead
develop
broadspectrum
neutral
antibodi
isol
b
cell
individu
partial
mimick
interact
receptor
studi
shown
interact
primarili
three
region
includ
loop
caus
conform
chang
bind
receptor
block
term
neutral
activ
similar
greater
unfortun
cellcel
fusion
inhibitori
activ
significantli
reduc
strain
appear
potent
mutant
screen
antibodi
librari
use
singlecel
clone
technolog
patient
current
undergo
clinic
trial
structurebas
mutant
enhanc
interact
bridg
sheet
compar
wider
neutral
profil
increas
neutral
activ
mutant
base
complex
structur
resist
strain
sequenc
analysi
design
activ
similar
greater
howev
resist
strain
effect
combin
therapi
mice
infect
reduc
viral
escap
bnab
isol
hivinfect
patient
target
effect
neutral
activ
inhibit
strain
could
attribut
depend
conserv
region
avoid
interact
light
chain
region
consid
major
factor
resist
viru
antibodi
nonhuman
primat
model
mutant
show
signific
antivir
effect
current
undergo
clinic
trial
assess
whether
safe
inhibit
infect
human
patientderiv
bnab
target
result
nonhuman
primat
show
combin
significantli
reduc
viral
load
shiv
longterm
protect
effect
repeat
lowdos
shiv
challeng
first
phase
clinic
trial
show
good
pharmacokinet
properti
effect
inhibit
viremia
patient
day
although
patient
develop
strain
short
period
time
worth
note
passiv
immun
acceler
clearanc
infect
cell
phase
iia
clinic
trial
data
show
effect
inhibit
viral
rebound
patient
treatment
interrupt
addit
cellular
immun
humor
immun
found
patient
treat
also
known
bnab
isol
elit
control
infect
clade
recombin
exhibit
broadspectrum
neutral
activ
similar
latter
two
isol
patient
infect
singl
subtyp
therefor
induct
bnab
target
depend
viral
subtyp
bnab
differ
recognit
pattern
differ
way
access
kappa
antibodi
target
discontinu
epitop
identifi
earli
subsequ
neutral
activ
evalu
cocryst
structur
show
conform
recognit
poorli
compat
viru
spike
result
low
neutral
activ
although
decad
sinc
clinic
trial
carri
progress
occur
long
time
human
mab
target
could
neutral
divers
primari
isol
fulli
protect
hupblscid
mice
infect
vivo
interestingli
fab
exert
inhibitori
activ
upon
entri
viru
cell
therefor
thought
dual
role
act
infect
subsequ
structur
env
extens
studi
provid
basi
epitop
studi
bnab
bind
play
key
role
first
step
viral
entri
solubl
contain
four
extracellular
immunoglobulin
homolog
domain
compet
receptor
ligand
earliest
candid
consid
develop
potenti
antihiv
drug
found
first
two
extracellular
domain
could
also
simul
receptor
bind
seri
antivir
test
carri
cell
anim
model
clinic
trial
result
show
high
activ
vitro
vivo
howev
halflif
rel
short
patient
viru
rebound
quickli
show
evid
treatment
effect
addit
low
concentr
could
enhanc
infect
clinic
strain
possibl
bind
result
exposur
corb
make
easi
viru
infect
neighbor
cell
drawback
greatli
reduc
clinic
applic
order
block
interact
receptor
effect
way
contain
bind
domain
scaffold
without
vh
vl
domain
design
expect
interrupt
bind
mimick
receptor
enhanc
peptid
valenc
flexibl
furthermor
possess
broad
neutral
activ
primari
isol
vitro
could
decreas
viral
load
murin
model
compar
bound
avid
virion
long
halflif
day
vivo
phase
ii
singledos
studi
show
pro
caus
respons
rate
viral
load
significantli
reduc
sever
week
posttreat
howev
intraven
administr
drug
cost
may
obstacl
clinic
use
smaller
form
contain
domain
design
base
crystal
structur
howev
unstabl
neutral
environ
lower
affin
recent
use
power
larg
phage
display
librari
errorpron
pcr
technolog
dr
dimitrov
colleagu
identifi
two
stabl
mutant
could
express
abundantli
e
coli
high
solubl
stabil
neutral
environ
vitro
antivir
experi
display
could
inhibit
multipl
strain
low
nm
level
exhibit
lower
bind
human
blood
cell
line
also
resist
trypsin
digest
human
serum
degrad
group
also
identifi
mutant
mutat
phage
display
librari
exhibit
better
lytic
express
thermost
specif
neutral
activ
subsequ
gener
sever
bifunct
multival
protein
link
corbstarget
neutral
antibodi
domain
human
fc
fusion
protein
target
corb
exhibit
broadli
crossreact
except
potent
neutral
activ
potent
bnab
respect
furthermor
shown
higher
stabil
specif
lower
aggreg
propens
later
construct
mutant
prolong
halflif
mous
serum
recent
test
activ
combin
sever
current
use
ard
includ
zidovudin
nrti
efavirenz
nnrti
saquinavir
proteas
inhibitor
peptid
includ
sft
found
combin
exhibit
synergist
activ
infect
laboratoryadapt
primari
strain
includ
resist
nrti
peptidebas
entri
inhibitor
applic
combin
expect
reduc
dose
ard
test
therebi
reduc
treatment
cost
cytotox
base
region
short
scorpion
toxin
scyllatoxin
loop
amino
acid
peptid
mimick
synthes
pocket
conserv
hydrophob
pocket
bind
receptor
bind
conserv
pocket
thu
interfer
interact
five
addit
mutat
shown
bind
pocket
nm
affin
effect
inhibit
infect
laboratoryadapt
strain
characterist
bind
studi
like
induc
conform
chang
bind
expos
bind
epitop
antibodi
epitop
overlap
corb
therefor
bind
could
block
bind
coreceptor
optim
interact
amino
acid
mimet
peptid
design
affin
env
inhibit
activ
effici
effect
strain
deriv
neutral
profil
similar
without
signific
improv
activ
mimet
target
pocket
deriv
includ
compos
amino
acid
extens
studi
inhibit
pseudoviru
pm
nm
level
induc
shed
high
concentr
result
reduct
new
viral
particl
releas
infect
cell
addit
resist
rhesu
macaqu
infect
shiv
expect
act
microbicid
prevent
sexual
transmiss
use
phagedisplay
peptid
librari
novel
peptid
inhibit
interact
found
inhibit
interact
nmr
structur
analysi
show
capabl
form
tight
ring
structur
upon
bind
followup
result
show
six
amino
acid
psfdlq
call
middl
play
crucial
role
activ
hexametr
linear
peptid
exhibit
lower
furthermor
ad
cystein
end
let
form
ring
peptid
cqpsfdlqc
show
even
lower
howev
current
literatur
could
find
relat
studi
report
inhibitori
activ
peptid
cellcel
fusion
well
varieti
strain
therefor
beg
assess
use
random
phage
librari
cyclin
peptid
ferrer
harrison
screen
peptid
interact
inhibit
bind
three
differ
hiv
strain
fourdomain
solubl
interestingli
could
also
inhibit
interact
mab
analysi
bind
site
suggest
inhibitori
activ
mutant
virus
reduc
significantli
mutat
residu
make
contact
locat
near
result
suggest
bind
mechan
differ
possibl
interact
stabil
unligand
rather
activ
one
result
inabl
interact
receptor
subsequ
interact
studi
std
nmr
model
bind
differ
state
propos
subtl
differ
reveal
deriv
show
inhibitori
activ
nm
level
viral
infect
experi
nm
bal
strain
howev
compar
optim
still
need
done
addit
common
drawback
among
human
bodi
modifi
exogen
protein
like
induc
specif
antibodi
would
neg
impact
inhibitori
activ
halflif
limit
clinic
use
therapeut
agent
hivneutr
antibodi
recogn
epitop
induc
bind
epitop
gener
overlap
corb
therefor
antibodi
inhibit
bind
coreceptor
singlestrand
human
antibodi
domain
target
obtain
screen
human
antibodi
variabl
domain
librari
use
env
later
mutant
higher
neutral
activ
screen
antibodi
small
molecular
weight
short
halflif
use
construct
bimolecular
fusion
protein
sever
wellknown
antibodi
report
includ
nterminu
coreceptor
sulfat
tyrosin
antibodi
contain
sulfat
tyrosin
includ
shown
stronger
affin
without
sulfat
tyrosin
two
sulfat
tyrosin
loop
stabil
intramolecular
interact
loop
studi
found
sulfat
peptid
amino
acid
deriv
loop
serv
structur
function
mimet
nterminu
act
directli
corb
loop
manner
therebi
block
bind
coreceptor
inhibit
infect
tyssulf
ntermin
mimet
peptid
target
bind
site
effect
inhibit
infect
cell
shown
compet
bind
establish
intermolecular
interact
corb
loop
unlik
restrict
coreceptor
tropism
broad
spectrum
activ
moreov
sulfat
peptid
deriv
cdr
region
antibodi
inhibit
bind
ccr
coreceptor
manner
howev
inhibitori
activ
peptid
level
optim
need
similarli
potent
mab
isol
patient
compar
earlier
bnab
higher
neutral
activ
broad
spectrum
differ
subtyp
pseudoviru
neutral
experi
neutral
epitop
mainli
depend
specif
posit
nlink
glycosyl
loop
glycan
profil
howev
gradual
increas
resist
bnab
viru
evolut
process
studi
shown
monoclon
antibodi
ibalizumab
imab
construct
bispecif
antibodi
high
inhibitori
activ
also
effect
inhibit
infect
strain
recent
studi
found
effici
recogn
cell
induc
cell
clearanc
antibodydepend
complementmedi
lysi
adcml
antibodydepend
cellmedi
cytotox
adcc
therefor
bnab
use
combin
maxim
clearanc
hivinfect
cell
hiv
cure
four
bnab
deriv
clonal
lineag
isol
individu
recogn
conform
epitop
similar
epitop
mainli
neutral
tier
rather
tier
primari
isol
strongest
neutral
activ
mean
median
respect
primari
isol
pgt
class
antibodi
includ
isol
elit
control
infect
antibodi
exhibit
differ
neutral
activ
potent
bnab
differ
subtyp
pseudoviru
howev
later
studi
found
circul
clade
c
patient
could
escap
neutral
glycan
specif
crystal
structur
complex
indic
bind
shorter
within
loop
sinc
loop
highli
variabl
easili
mask
env
trimer
spike
role
antibodi
humor
immun
may
limit
clonal
variant
pgt
target
loop
isol
patient
infect
subtyp
bnab
neutral
activ
vitro
vivo
although
strain
resist
found
phase
clinic
trial
combin
result
longterm
effect
inhibit
viral
load
patient
resist
strain
found
lectin
found
interact
result
interfer
bind
receptor
therebi
demonstr
activ
howev
specif
antivir
mechan
action
still
unclear
nonetheless
mechan
may
interact
glycan
exert
antivir
effect
cyanovirinn
cvn
protein
deriv
cyanobacteria
irrevers
inactiv
siv
low
nm
level
griffithsin
grft
protein
deriv
red
alga
shown
inhibit
infect
envmedi
cellcel
fusion
pm
level
delet
rearrang
glycosyl
site
may
confer
toler
cvn
grft
howev
cvn
grft
ampli
express
e
coli
low
cytotox
therefor
expect
develop
microbicid
recent
sever
legum
lectin
includ
conbr
canavalia
brasiliensi
lectin
conm
canavalia
maritima
lectin
dlasil
dioclea
lasiocarpa
lectin
dscler
l
dioclea
sclerocarpa
lectin
hha
hyppeastrum
hybrid
agglutinin
show
low
nm
level
inhibitori
activ
thu
deserv
studi
humanderiv
scfv
screen
phage
display
librari
target
nhr
pocketbind
region
block
infect
differ
hiv
isol
addit
attach
cholesterol
increas
membran
bind
antivir
activ
consist
result
obtain
link
cholesterol
antihiv
peptid
mab
mab
isol
hivinfect
individu
whose
epitop
cover
conserv
hydrophob
pocket
region
nhr
surprisingli
neutral
activ
differ
target
cell
vari
greatli
subsequ
crystal
structur
combin
reveal
combin
nhr
epitop
differ
angl
may
allow
exhibit
higher
neutral
activ
broad
profil
antibodi
target
nhr
rabbit
scfv
human
fab
epitop
partial
overlap
epitop
exhibit
moder
neutral
activ
differ
hiv
strain
addit
epitop
murin
monoclon
antibodi
may
coincid
target
block
antifus
effect
bind
nhrderiv
peptid
amino
acid
recombin
peptid
contain
entir
sequenc
higher
helic
bind
abil
nhr
show
inhibitori
activ
similar
vitro
much
better
importantli
deriv
could
highli
express
e
coli
system
per
liter
cultur
although
need
optim
still
excit
news
futur
low
cost
largescal
product
group
also
design
seri
recombin
chrpeptid
fusion
inhibitor
residu
residu
report
low
inhibitori
activ
interestingli
found
purif
method
recombin
peptid
close
relat
antihiv
activ
exampl
chrpeptid
purifi
gstpresciss
proteas
system
lowest
activ
may
caus
mani
reason
addit
proteas
cleavag
site
deterg
elut
buffer
design
link
via
flexibl
linker
coval
attach
greatli
enhanc
enrich
around
target
show
high
activ
broad
spectrum
moreov
fragment
form
high
structur
enabl
express
e
coli
good
resist
proteas
recombin
protein
consist
residu
residu
residu
wherein
residu
replac
ccg
result
format
trimer
trimer
exhibit
potent
antihiv
activ
vitro
low
nm
envmedi
cellcel
fusion
group
success
design
produc
recombin
chimera
protein
fusion
inhibitor
includ
design
fuse
nhrpeptid
trimer
motif
foldon
residu
form
phage
fibritin
highli
hydrophil
highli
trimer
serv
stabil
chimer
trimer
physiolog
condit
order
allow
nhrpeptid
part
effici
interact
chr
express
recombin
protein
e
coli
highli
solubl
abl
form
trimer
conform
neutral
buffer
viral
inhibit
activ
potent
peptid
potent
peptid
quit
similar
low
nm
rang
howev
sensit
proteolyt
enzym
low
ph
environ
addit
two
cystein
nterminu
constitut
resist
heat
pepsin
proteinas
k
approxim
activ
inhibit
iiib
bal
infect
addit
sinc
inhibitori
activ
affect
semen
vagin
secret
also
show
promis
develop
microbicid
varieti
antibodi
target
nhrchr
complex
found
human
monoclon
antibodi
fabd
murin
monoclon
antibodi
howev
neutral
hiv
physiolog
temperatur
interestingli
antibodi
inhibit
hiv
envmedi
cellcel
membran
fusion
subtemperatur
believ
membran
fusion
physiolog
temperatur
may
rapid
process
steric
hindranc
hinder
antibodi
bind
molecular
dynam
subtemperatur
slow
prolong
fusion
process
allow
antibodi
activ
use
yeast
twohybrid
technolog
screen
natur
hiv
protein
inhibitor
final
obtain
peptid
deriv
human
protein
deriv
could
inhibit
broad
rang
strain
low
level
includ
strain
interestingli
peptid
bound
block
format
suggest
membran
fusion
process
complic
thought
fusion
complet
immedi
format
seri
previous
unknown
molecular
event
like
take
place
miyauchi
provid
compel
evid
show
hiv
enter
cell
primarili
endocytosi
may
prove
similar
view
viru
target
cell
membran
start
fuse
immedi
chang
conform
cours
view
current
controversi
addit
use
recombin
solubl
bait
human
bone
marrow
cdna
librari
screen
yeast
twohybrid
techniqu
endocyt
protein
bind
identifi
analysi
reveal
residu
deriv
cterminu
effect
inhibit
infect
intens
research
found
inhibit
membran
fusion
primarili
interact
residu
nhr
expos
surfac
block
format
addit
mediat
entri
epiderm
cell
lack
receptor
reveal
infect
cell
manner
although
inhibit
activ
infect
low
level
use
probe
studi
membran
fusion
mechan
lead
develop
hiv
entri
inhibitor
target
mper
highli
conserv
region
figur
varieti
human
monoclon
antibodi
found
target
differ
epitop
mper
neutral
differ
subtyp
therefor
mper
also
one
import
target
vaccin
design
neutral
multipl
laboratoryadapt
clinic
strain
exert
antivir
activ
interact
linear
epitop
form
eldkwa
residu
sequenc
mper
region
subsequ
anoth
human
monoclon
antibodi
also
obtain
specif
recogn
rel
conserv
tryptophanrich
linear
epitop
residu
locat
mper
although
broadspectrum
neutral
activ
except
strain
subtyp
b
subtyp
addit
autoreact
bind
phospholipid
bilay
mper
region
believ
caus
toxic
side
effect
bnab
deriv
patient
whose
epitop
contain
residu
transmembran
region
tm
entir
mper
unlik
higher
neutral
activ
specif
reactiv
selfantigen
identifi
hydrophob
region
optim
heavi
light
chain
mutant
success
produc
higher
solubl
also
retain
neutral
activ
profil
similar
use
crossmab
technolog
research
construct
bispecif
antibodi
librari
screen
excel
broadspectrum
neutral
antibodi
neutral
pseudovirus
low
human
mous
model
posit
effect
prevent
treatment
infect
studi
shown
main
reason
high
neutral
activ
ibalizumab
imab
compon
guid
enrich
site
fusion
occur
enabl
antibodi
exert
neutral
activ
effici
higher
solubl
stabil
obtain
introduc
hydrophil
amino
acid
mutat
moreov
vitro
vivo
antivir
activ
slightli
higher
kirchhoff
group
use
comprehens
peptid
librari
gener
human
hemofiltr
make
largescal
screen
obtain
peptid
virip
deriv
human
natur
protein
instead
interact
nhr
chr
peptid
bound
fp
deriv
could
inhibit
infect
divers
strain
includ
resist
vitro
low
level
later
virip
use
construct
bispecif
molecul
higher
inhibitori
activ
impli
domain
may
also
serv
might
design
drug
target
develop
novel
hiv
entri
inhibitor
also
provid
import
detail
membran
fusion
process
particular
whether
fp
domain
expos
outsid
made
conform
chang
virip
also
use
molecul
probe
studi
function
fp
membran
fusion
process
present
report
coinfect
gbvc
lymphotrop
viru
replic
primari
b
lymphocyt
benefici
patient
diseas
differ
view
prevail
safeti
reason
research
use
gbvc
protein
studi
activ
found
peptid
deriv
may
inhibit
infect
interact
fp
acid
peptid
screen
protein
overlap
peptid
librari
broad
spectrum
inhibitori
activ
peptid
deriv
protein
inhibitori
activ
origin
isol
compar
first
gener
chrpeptid
consist
three
peptid
deriv
chr
domain
includ
residu
name
later
residu
residu
report
jiang
et
al
new
york
blood
center
wild
et
al
duke
univers
lu
et
al
mit
respect
new
york
blood
center
file
patent
us
patent
march
issu
august
duke
univers
file
patent
us
patent
june
issu
novemb
group
duke
univers
establish
pharmaceut
compani
name
trimeri
inc
develop
fusion
inhibitorbas
antihiv
drug
amino
acid
overlap
trimeri
licens
new
york
blood
center
patent
develop
enfuvirtid
approv
us
fda
first
hiv
fusion
inhibitorbas
antihiv
drug
clinic
use
treat
hivinfect
patient
fail
respons
current
ard
howev
clinic
applic
limit
low
potenc
less
potent
short
halflif
h
thu
requir
subcutan
inject
twice
daili
dose
mg
caus
sever
inject
site
reaction
previou
studi
shown
unlik
contain
pocketbind
sequenc
pbd
critic
interact
chrpeptid
viral
nhr
form
stabl
inhibit
hiv
fusion
lack
pbd
thu
interact
viral
nhr
effect
block
hiv
infect
howev
contain
tryptophanrich
motif
trm
lipidbind
region
lbd
thu
believ
need
lbd
interact
target
cell
membran
enhanc
interact
viral
nhr
domain
zhang
et
al
shown
abl
interact
peptid
contain
partial
sequenc
nhr
domain
fusion
peptid
proxim
region
fppr
downstream
region
cterminu
fp
form
recent
demonstr
inhibit
format
nativ
cell
earli
late
stage
fusion
interact
fppr
may
play
import
role
inhibitori
activ
base
newli
clarifi
mechan
action
design
new
peptid
ad
addit
trm
cterminu
found
exhibit
significantli
improv
activ
target
tripl
site
includ
nhr
fppr
fp
second
gener
chrpeptid
mutant
peptid
activ
potent
analog
sifuvirtid
albuvirtid
seri
chrpeptid
mutant
design
improv
solubl
nhrbind
affin
antivir
potenc
halfliv
fujii
group
modifi
peptid
increas
solubl
enhanc
interact
nhr
introduc
eekk
doubl
saltbridg
first
design
peptid
show
activ
similar
interact
nhr
strongli
solubl
thu
better
drug
candid
develop
shorten
kept
similar
inhibitori
potenc
strategi
appli
result
potent
increas
compar
also
effect
isol
develop
trimeri
inc
hope
replac
contain
pbd
lbd
although
enhanc
activ
strain
phase
ii
clinic
trial
termin
report
side
effect
design
base
sequenc
peptid
residu
vitro
show
stronger
antivir
activ
infect
diverg
strain
includ
resist
particular
maintain
stabl
trimer
structur
neutral
buffer
characterist
contribut
enhanc
antihiv
potenc
stabil
howev
studi
prove
certain
chrpeptid
high
helic
stabl
bind
nhr
tm
valu
show
littl
antihiv
activ
therefor
appropri
affin
nhr
proper
helic
may
lead
highest
antihiv
activ
sifuvirtid
novel
peptid
inhibitor
develop
fusogen
inc
sequenc
deriv
mutat
spiral
properti
enhanc
similar
sifuvirtid
strongli
bound
nhrpeptid
significantli
inhibit
format
also
potent
antihiv
activ
vitro
especi
strain
sifuvirtid
success
pass
phase
ii
clinic
trial
china
also
efficaci
sifuvirtid
monotherapi
mg
daili
equival
enfuvirtid
mg
twice
daili
http
wwwfusogencom
howev
develop
termin
unknown
reason
accord
crystal
structur
complex
form
nhrpeptid
design
substitut
three
residu
bound
nhrpeptid
ly
glu
convent
peptid
inhibitor
suscept
proteas
degrad
therefor
short
halflif
vivo
bind
serum
albumin
prolong
halflif
vivo
conserv
cy
residu
occur
differ
speci
albumin
human
cy
free
sulfhydryl
group
order
bind
peptid
thiol
group
albumin
differ
residu
modifi
maleimidopropion
acid
mpa
obtain
correspond
modifi
peptid
modifi
peptid
bound
human
serum
albumin
hsa
test
antihiv
activ
vitro
obtain
chemic
modif
residu
mpa
immunogen
halflif
rhesu
monkey
longer
clinic
trial
albuvirtid
administ
intraven
current
ard
week
could
effect
inhibit
infect
reduc
viral
load
therefor
approv
china
food
drug
administr
cfda
clinic
use
third
gener
chrpeptid
modifi
chrpeptid
activ
potent
includ
chrpeptid
contain
mthook
idl
anchor
lipopeptid
et
al
shown
peptid
residu
exhibit
potent
activ
deriv
inhibit
strain
also
strain
provid
novel
paradigm
develop
new
gener
entri
inhibitor
analysi
crystal
structur
form
nhrpeptid
reveal
form
hooklik
structur
call
mthook
stabil
interact
chrpeptid
pocketform
domain
pfd
nhr
significantli
increas
inhibitori
activ
chrpeptid
therefor
mthook
wide
use
design
chrpeptid
peptid
contain
mthook
pbd
high
bind
stabil
antivir
activ
includ
strain
subsequ
short
peptid
contain
mthook
sequenc
design
highli
stabl
helic
peptid
broadspectrum
inhibitori
activ
differ
subtyp
includ
strain
strain
howev
compar
low
inhibitori
activ
chrpeptid
deriv
chr
contain
natur
sequenc
may
therefor
crossreact
preexist
antibodi
serum
hiv
patient
order
avoid
phenomenon
design
artifici
peptid
ad
mthook
nterminu
stabil
interact
nhr
obtain
fold
singl
helix
interact
nhr
prevent
format
addit
superior
antivir
activ
antivir
profil
pharmacolog
properti
surprisingli
preexist
antibodi
patient
fail
recogn
also
enhanc
antihiv
activ
mechan
still
worth
explor
use
comput
model
analyz
crystal
structur
nhr
trimer
found
shallow
pocket
nterminu
nhr
name
ntermin
hydrophob
pocket
nthp
consist
one
nhr
helix
residu
anoth
nhr
helix
residu
highli
conserv
among
differ
strain
hypothes
enhanc
bind
chrpeptid
nhr
nthp
could
increas
inhibitori
activ
therefor
design
seri
longchain
hydrophob
residu
cterminu
chrpeptid
wq
residu
target
nthp
expect
newli
design
peptid
wqidl
activ
inhibit
iiib
bal
infect
introduc
mthook
nterminu
wqidl
found
activ
mtwqidl
improv
may
mt
idl
enhanc
bind
wq
peptid
nhr
pfd
nthp
respect
peptid
wq
also
term
peptid
cp
cpidl
coupl
use
sggrgg
linker
form
complex
crystal
structur
indic
idl
tail
form
two
differ
conform
one
alphahelix
hooklik
structur
exhibit
broader
interact
nhr
wide
believ
lipid
lipopeptid
abl
anchor
peptid
cell
membran
result
elev
concentr
peptid
fusion
site
howev
klug
et
al
propos
differ
mechan
sphinganin
lipid
peptid
sphinganin
pbdk
peptid
peptid
deriv
pocketbind
domain
chr
region
jointli
disrupt
earli
late
event
membran
fusion
furthermor
lipopeptid
exhibit
prolong
halflif
vivo
unconjug
peptid
possibl
revers
bind
protein
serum
et
al
modifi
differ
lipid
eg
fatti
acid
cholesterol
sphingolipid
conjug
palmit
acid
respect
mtlink
methionin
replac
leucin
construct
mainli
target
pfd
nhr
inhibit
differ
clinic
isol
includ
strain
strain
addit
effect
inhibit
siv
infect
team
design
seri
lipopeptid
exampl
design
replac
ctermin
tryptophanrich
region
trm
interestingli
inhibit
cellcel
fusion
pseudoviru
entri
activ
complementari
thu
synergist
antivir
effect
similar
design
strategi
construct
replac
ctermin
trm
higher
inhibitori
activ
valu
pm
level
exhibit
synergi
previous
design
peptid
later
introduc
singl
amino
acid
mutat
ad
palmit
acid
obtain
lipopeptid
exhibit
high
antivir
activ
long
halflif
amino
acid
lipopeptid
design
base
analysi
structureact
relationship
contain
pbd
trm
cterminu
coupl
high
gene
barrier
long
halflif
also
inhibit
larg
number
isol
low
pm
level
also
high
activ
strain
lipopeptid
palmit
acid
modifi
exist
chrpeptid
contain
lack
pbd
lipopeptid
better
activ
halflif
genet
barrier
precursor
peptid
consequ
cost
larg
number
resist
strain
chrpeptid
emerg
greatli
limit
use
chrpeptid
whether
resist
lipopeptid
occur
futur
still
focu
attent
coval
bind
cholesterol
obtain
high
affin
lipid
raft
cell
membran
inhibit
format
viral
infect
activ
inhibit
multipl
isol
vitro
activ
indic
link
cholesterol
hrderiv
peptid
inhibitor
effect
strategi
increas
antivir
activ
furthermor
strategi
also
appli
enhanc
antivir
activ
fusion
inhibitori
peptid
envelop
virus
influenza
viru
suggest
role
cholesterol
design
entri
inhibitor
deserv
attent
contrast
palmit
acid
use
lipid
enhanc
interact
peptid
cell
membran
conveni
econom
cholesterol
sphingolipid
addit
enhanc
bind
lipid
palmit
acid
also
bind
human
serum
albumin
reduc
rate
glomerular
elimin
prolong
halflif
drug
vivo
lipid
raft
thought
hallmark
bud
entri
cell
macrophag
mani
glycosylphosphatidylinositol
gpi
anchor
protein
local
lipid
raft
anchor
gpi
shown
bind
lipid
raft
via
gpi
anchor
broadli
inhibit
infect
prove
inclus
substanc
capabl
bind
lipid
membran
hiv
inhibitor
effect
way
increas
activ
inhibitor
focu
develop
chrpeptid
aris
earli
discoveri
nhrderiv
peptid
interact
chr
inhibit
format
homolog
lower
inhibitori
activ
unstabl
summari
amino
acid
sequenc
nhrpeptid
inhibit
cellcel
fusion
activ
figur
nhrpeptid
acid
residu
deriv
nhr
interact
chrpeptid
deriv
chr
form
vitro
theoret
inhibitori
activ
infect
sinc
interact
viral
nhr
form
heterolog
thu
block
fusion
viral
cell
membran
howev
nhrderiv
nhrpeptid
tendenc
aggreg
neutral
buffer
strong
hydrophob
thu
exhibit
low
viral
fusion
inhibitori
activ
hundr
fold
lower
chrpeptid
peptid
e
g
design
replac
hydrophob
residu
e
g
posit
hydrophil
residu
nhrpeptid
interact
chr
form
remain
solubl
physiolog
solut
pb
e
g
show
inhibitori
activ
submicromolar
level
peptid
may
interact
viral
nhr
form
nonfunct
heterolog
nhr
trimer
result
inhibit
fusion
viral
target
cell
membran
shai
colleagu
shown
nhrpeptid
pbd
signific
inhibitori
activ
cellcel
fusion
becam
activ
nm
palmit
acid
conjug
n
terminu
c
terminu
interestingli
e
g
similar
mutat
e
g
exhibit
cell
fusion
inhibitori
activ
either
conjug
nterminu
ie
e
g
show
inhibitori
envmedi
cellcel
fusion
lower
suggest
mainli
target
chr
rather
intern
nhr
coiledcoil
group
also
demonstr
conjug
either
n
cterminu
result
increas
membran
fusion
inhibitori
activ
inhibitori
activ
e
g
stronger
e
g
suggest
planar
orient
peptid
endogen
nhr
region
cell
membran
suggest
planar
orient
peptid
well
endogen
nhr
region
cell
membran
effort
focus
enhanc
nhrpeptid
solubl
maintain
natur
trimer
structur
kim
ad
highli
trimer
model
peptid
sequenc
iq
iz
other
form
recombin
highli
solubl
form
trimer
structur
increas
antihiv
activ
low
nm
rang
mutat
nhrpeptid
howev
quit
stabl
compar
chrpeptid
therefor
maintain
antivir
activ
long
nevertheless
studi
nhrpeptid
fusion
inhibitor
still
attract
inhibitor
advantag
target
chr
may
avoid
crossdrug
resist
current
use
fusion
inhibitor
chrpeptid
fusion
inhibitor
develop
bnab
isol
patient
neutral
tier
isol
epitop
includ
asn
asn
inner
region
loop
loop
may
involv
adjac
amino
acid
sinc
epitop
span
nativ
env
trimer
becom
first
bnab
deriv
human
act
two
subunit
env
bnab
produc
primarili
natur
infect
target
conserv
interfac
recogn
glycosyl
site
jrcsf
strain
env
higher
neutral
activ
complex
caus
chang
conform
studi
shown
bind
expos
epitop
interfac
exert
neutral
activ
therefor
compet
bnab
target
bind
viral
particl
mani
individu
antibodi
similar
open
possibl
make
vaccin
similar
antibodi
furthermor
construct
immunogen
structur
similar
natur
env
trimer
may
import
role
induc
antibodi
bnab
deriv
chronic
infect
individu
inhibit
conform
chang
block
viral
entri
like
epitop
contain
also
target
nterminu
fp
neutral
profil
limit
neutral
rate
differ
strain
mutat
fp
caus
sever
resist
howev
molecular
dynam
indic
nterminu
fp
expos
solut
mean
discoveri
antibodi
suggest
fp
also
import
antibodi
recognit
epitop
bnab
isol
elit
control
infect
target
interfac
fp
stabil
highli
unstabl
env
trimer
structur
compar
broader
neutral
profil
neutral
rate
bnab
target
interfac
isol
elit
control
infect
interact
residu
glycan
especi
fp
fppr
neutral
differ
subtyp
strain
median
valu
although
neutral
activ
rang
promin
discoveri
antibodi
reveal
conserv
fp
target
bnab
mab
isol
patient
moder
broadspectrum
neutral
activ
similar
epitop
target
interfac
mechan
neutral
activ
may
one
destroy
function
integr
env
trimer
caus
shed
sensit
antibodyresist
strain
target
patient
therefor
combin
broaden
neutral
profil
mab
recent
isol
patient
target
contact
surfac
epitop
contain
cterminu
partial
overlap
epitop
howev
neutral
rang
limit
strain
ctermin
mutat
escap
neutral
mab
obtain
screen
phage
antibodi
fab
librari
gp
specif
mab
librari
use
competit
antigen
pan
cap
methodolog
conform
epitop
recogn
contain
ntrimer
structur
howev
neutral
activ
neutral
rang
may
limit
applic
bival
chimer
protein
construct
fuse
first
two
extracellular
domain
unlik
entri
inhibitor
trigger
earli
exposur
prior
viral
fusion
rapidli
inactiv
viral
particl
bind
caus
conform
chang
expos
result
format
prehairpin
fusion
intermedi
pfi
bind
expos
pfi
caus
cellfre
viru
rapidli
inactiv
inactiv
differ
isol
rang
nm
make
effect
nm
produc
larg
quantiti
e
coli
exhibit
synergi
antivir
drug
rather
mediat
infect
like
chimer
protein
serv
dual
barrier
infect
first
inactiv
unabl
infect
target
cell
second
viru
evad
first
attack
inhibit
viralcel
fusion
fusion
inhibitor
bispecif
protein
coval
link
amino
acid
chrpeptid
target
nhr
similar
interact
expos
nhr
follow
target
nhr
inactiv
cellfre
viru
unlik
bispecif
protein
caus
envmedi
cell
infect
probabl
owe
import
role
consist
grft
griffithsin
target
peptid
amino
acid
nterminu
target
nhr
inhibit
cellcel
fusion
infect
midnanomolar
midpicomolar
level
respect
inhibitori
activ
effect
grft
combin
demonstr
grft
activ
increas
coupl
drug
differ
target
addit
sinc
resist
strain
grft
emerg
dual
target
may
increas
genet
barrier
dualtarget
recombin
protein
form
coval
attach
peptid
target
nhr
cy
posit
phe
posit
target
recombin
protein
inhibit
activ
fusion
assay
significantli
higher
individu
compon
although
differ
signific
inhibit
fusion
assay
howev
simplic
prepar
recombin
protein
strategi
use
refer
guid
synthesi
recombin
protein
sinc
first
peptidebas
hiv
entri
inhibitor
enfuvirtid
approv
clinic
use
us
fda
nine
seri
protein
peptidebas
hiv
entri
inhibitor
develop
preclin
clinic
studi
tabl
differ
current
ard
must
enter
host
cell
inhibit
hiv
replic
entri
inhibitor
block
hiv
entri
host
cell
target
site
viral
surfac
protein
includ
corb
variabl
loop
region
glycan
fp
nhr
chr
mper
therefor
big
molecul
protein
peptid
without
cellpenetr
abil
act
surfac
cell
block
viru
entri
cell
transmiss
cell
expect
advers
effect
function
intracellular
protein
high
specif
potenc
safeti
advantag
protein
peptidebas
hiv
entri
inhibitor
high
cost
product
lack
oral
avail
disadvantag
compar
current
ard
howev
may
concern
use
treat
patient
earli
stage
highli
pathogen
viru
infect
high
mortal
shortterm
week
inject
protein
peptidebas
viru
entri
inhibitor
high
dosag
expect
save
patient
live
current
number
proteinbas
hiv
entri
inhibitor
particularli
neutral
antibodi
high
specif
efficaci
safeti
well
long
halflif
vivo
report
alreadi
undergo
clinic
trial
unlik
proteinbas
hiv
entri
inhibitor
must
store
transport
low
temperatur
peptidebas
hiv
entri
inhibitor
store
transport
normal
temperatur
howev
peptidebas
hiv
entri
inhibitor
gener
suscept
proteas
degrad
thu
shorter
halflif
vivo
studi
attempt
use
e
coli
express
system
conjug
techniqu
reduc
cost
inhibitor
enhanc
stabil
addit
emerg
drugresist
strain
also
urgent
problem
solv
therefor
optim
sequenc
structur
peptidebas
hiv
inhibitor
purpos
prolong
halflif
enhanc
antihiv
potenc
improv
druggabl
delay
emerg
drugresist
strain
combin
use
two
hiv
entri
inhibitor
differ
target
essenti
futur
develop
